The Groundbreaking Nagoya University Discovery in Ovarian Cancer Metastasis

Researchers at Nagoya University's Graduate School of Medicine have uncovered a critical mechanism explaining the rapid peritoneal spread of epithelial ovarian cancer (EOC), the most prevalent and lethal form of ovarian malignancy. Published on February 6, 2026, in the prestigious journal Science Advances, the study reveals how floating ovarian cancer cells in abdominal fluid recruit nearby mesothelial cells to form hybrid clusters known as ascites-derived cancer-mesothelial spheroids (ACMSs). These clusters enable mesothelial cells to lead the invasion into surrounding tissues, paving pathways for cancer cells to follow and metastasize swiftly. Led by Dr. Kaname Uno, a former PhD student now serving as a Visiting Researcher, alongside key contributors Masato Yoshihara and Professor Hiroaki Kajiyama from the Department of Obstetrics and Gynecology, this work challenges previous understandings of cancer dissemination and opens new therapeutic avenues.

The discovery stems from meticulous analysis of patient ascites fluid, where nearly all EOC cells (99.5%) exist as spheroids, over 60% incorporating mesothelial cells. This collaboration transforms protective mesothelial cells into unwitting accomplices, accelerating what makes ovarian cancer notoriously hard to treat at advanced stages.

Ovarian Cancer Burden in Japan: Statistics and Challenges

In Japan, ovarian cancer represents a significant public health concern, with projected incidence reaching approximately 13,400 cases in 2025 according to national cancer statistics. Despite comprising about 2.5% of female cancers, it accounts for a disproportionate share of deaths due to late diagnosis—often when peritoneal metastasis has already occurred. The five-year survival rate hovers around 45-50% overall, plummeting to under 30% for advanced stages. Japan's aging population exacerbates this, with incidence rates showing a gradual upward trend (annual percent change around 1-2% in recent decades).

Peritoneal metastasis, where cancer spreads within the abdominal cavity, is the primary cause of fatality. Ascites accumulation, present in up to 90% of advanced cases, facilitates this process by harboring free-floating cancer cells. Nagoya University's findings directly address this gap, highlighting why standard chemotherapy often fails against these disseminated clusters.

For those pursuing careers in oncology, Japan's robust funding through the Japan Agency for Medical Research and Development (AMED) supports such pivotal research. Explore research jobs in cancer biology at leading institutions like Nagoya University.

What Are Mesothelial Cells and Their Normal Role?

Mesothelial cells form a thin, protective layer of simple squamous epithelium lining the peritoneal cavity, pleura, and pericardium. They secrete lubricating fluid to minimize friction between organs during movement and act as a barrier against pathogens and injury. In healthy individuals, these cells maintain homeostasis in the abdominal cavity, producing hyaluronic acid-rich fluid.

In cancer contexts, however, their proximity to tumors turns them into potential allies. Single-cell RNA sequencing (scRNA-seq) analyses confirm mesothelial cells dominate ascites (up to 30-50%), distinguished by markers like HBME1 (Hector Battifora Mesothelial cell-1), podoplanin, and WT1 (Wilms' Tumor 1). Nagoya researchers validated this using multiphoton microscopy and lineage tracing in mouse models (Wt1-CreERT2; tdTomato), proving their non-malignant origin.

Step-by-Step: How EOC Cells Recruit Mesothelial Partners

The recruitment process unfolds rapidly in ascites:

• Step 1: EOC cells shed into peritoneal fluid form loose spheroids, surviving anoikis (detachment-induced cell death) through cell-cell adhesions.
• Step 2: Nearby mesothelial cells adhere via direct contact, accelerated by EOC-secreted Transforming Growth Factor Beta 1 (TGF-β1), a multifunctional cytokine regulating cell proliferation, differentiation, and extracellular matrix (ECM) production.
• Step 3: Within 2-4 hours, hybrid ACMSs emerge, with mesothelial cells comprising 20-40%—more compact and interconnected than mono-cultures.
• Step 4: TGF-β1 stimulates mesothelial cells, upregulating hypoxia-inducible factor 1-alpha (HIF1A) under spheroid-induced hypoxia, triggering invasive gene programs.

RNA sequencing of fluorescence-sorted ACMS cells showed dramatic shifts in mesothelial transcriptomes (e.g., TGF-β/Notch/PI3K pathways upregulated), while EOC changes were minimal.

The Invasion Process: Mesothelial Cells as Pioneers

In ACMSs, mesothelial cells transform into 'leader cells,' forming invadopodia—actin-rich protrusions that degrade ECM. Key player: Fascin-1 (FSCN1), an actin-bundling protein enabling filopodia/lamellipodia assembly, upregulated alongside MMP14 (matrix metalloproteinase 14) and myosin X.

Time-lapse imaging revealed mesothelial cells breaching collagen gels or mesothelial monolayers first (clearance within hours), creating tunnels for trailing EOC cells. In ex vivo human omentum models, ACMSs invaded deeper (quantified via confocal z-stacks) and formed more metastases than EOC alone.

This division of labor explains rapid dissemination: mesothelial cells handle tough barrier penetration, shielding cancer cells.

Photo by Steve Johnson on Unsplash

Robust Evidence from Multi-Modal Experiments

Nagoya team's rigor spans scales:

• In vitro: 3D collagen invasion assays (depth/area metrics), FITC-gelatin degradation spots.
• Ex vivo: Patient omentum slices seeded with spheroids, metastasis counts post-72 hours.
• In vivo: Nude mice intraperitoneally injected with GFP-labeled ACMSs showed higher bioluminescence tumor burden, ascites ACMS prevalence, and omental invasion vs. EOC spheroids.

Clinically, stromal fascin-1 expression correlated with poorer progression-free survival (Kaplan-Meier, P=0.030, n=large cohorts).

ACMSs Confer Chemotherapy Resistance

ACMSs protect EOC from cisplatin (platinum-based standard): flow cytometry showed reduced apoptosis (annexin V+). Mesothelial presence induces anoikis resistance and hypoxia tolerance, mimicking tumor microenvironment.

Positive ascites cytology predicts worse outcomes (HR 1.4-2.0), underscoring ACMS role in recurrence.

Link to academic career advice for aspiring oncologists researching resistance mechanisms.

Promising Therapies: Targeting the Mesothelial Alliance

The study spotlights TGF-β1 and fascin-1 as druggable targets. TGF-β inhibitors (e.g., galunisertib) are in trials globally, including Japan. Fascin-1 inhibitor NP-G2-044 (Prilukae) shows promise in phase 2/3 trials for platinum-resistant ovarian cancer, safe in combo with doxorubicin, disrupting metastasis and boosting immunity.

Stromal targeting could enhance chemo efficacy. Read the full paper. Nagoya press release: here.

Full text on PMC: access here.

Nagoya University: A Hub for Gynecologic Oncology Research

Nagoya University, a top-tier Japanese institution, excels in translational cancer research. The Kajiyama lab has pioneered ovarian cancer studies, including proteomics for diagnostics and ascites cytology prognostics. Dr. Uno's trajectory—from PhD to lead author in Science Advances—exemplifies mentorship success.

Japan's higher education invests heavily in such teams via JSPS grants. For faculty positions, visit professor jobs or Japan academic listings on AcademicJobs.com.

Implications for Higher Education and Research Careers in Japan

This publication elevates Nagoya U's global profile, attracting international collaborations like Joint PhD programs. It underscores Japan's rising cancer research prowess, with AMED funding breakthroughs.

Postdocs and lecturers: Opportunities abound in postdoc roles and lecturer jobs focusing on precision oncology.

Photo by Bioscience Image Library by Fayette Reynolds on Unsplash

Future Outlook: From Bench to Clinical Trials

Ongoing: Fascin inhibitors entering phase 3; TGF-β combos. Nagoya plans human trials targeting ACMS. Personalized medicine via ascites scRNA-seq could predict metastasis risk.

Stakeholders—patients, policymakers—gain actionable insights. Researchers, leverage postdoc advice.

Why This Matters: Empowering Patients and Researchers

Nagoya's insight demystifies ovarian cancer lethality, promising better outcomes. Share professor insights on Rate My Professor, seek higher ed jobs, or career tips at Higher Ed Career Advice. Explore university jobs in Japan to contribute.